Collaborators from Cedars-Sinai to present
human proteomics data supporting the potential benefits of Auxora™
in severe acute pancreatitis (AP)
LA JOLLA, Calif.,
May 7,
2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica")
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium (CRAC)
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced the acceptance of an
abstract for poster presentation by a collaborator from
Cedars-Sinai Medical Center at the upcoming Digestive Disease Week
(DDW) 2024 being held May 18-21 in
Washington, DC and virtually.
Details for the presentation are as follows:
Presentation Title: Serum Proteomics Reveals That the
Orai1 Inhibitor Auxora May Provide Benefits in Severe Acute
Pancreatitis Similar to Those Seen in COVID-19 Pneumonia
Presenter: Richard T.
Waldron, Ph.D., Cedars-Sinai
Session Date and Time: Saturday,
May 18, 12:30-1:30 p.m. ET
Session Title: Clinical Acute Pancreatitis:
Management
Poster #: Sa1468
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC
channels to modulate the immune response and protect against tissue
cell injury, with the potential to provide therapeutic benefits in
life-threatening inflammatory and immunologic diseases for which
there are currently no approved therapies. CalciMedica's lead
product candidate Auxora™, a proprietary, intravenous-formulated
CRAC channel inhibitor, has demonstrated positive and consistent
clinical results in multiple completed efficacy clinical trials.
CalciMedica is currently conducting a Phase 2b trial (called CARPO – NCT04681066) for AP with
SIRS, with topline data expected in the second quarter of 2024, as
well as supporting the ongoing Phase 1/2 AIPT study (called CRSPA –
NCT04195347), with data expected in 2025. CalciMedica plans to
initiate patient enrollment in its Phase 2 study (called KOURAGE –
NCT06374797) in AKI with associated AHRF in the second quarter of
2024 with data expected in 2025. CalciMedica was founded by
scientists from Torrey Pines Therapeutics and the Harvard CBR
Institute for Biomedical Research, and is headquartered in
La Jolla, CA. For more
information, please visit www.calcimedica.com.
About DDW
Digestive Disease Week® (DDW) is
the largest international gathering of physicians, researchers and
academics in the fields of gastroenterology, hepatology, endoscopy
and gastrointestinal surgery. Jointly sponsored by the American
Association for the Study of Liver Diseases (AASLD), the American
Gastroenterological Association (AGA), the American Society for
Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of
the Alimentary Tract (SSAT), DDW is an in-person and online meeting
from May 18-21, 2024. The meeting
showcases more than 5,600 abstracts and hundreds of lectures on the
latest advances in GI research, medicine and technology. More
information can be found at www.ddw.org.
Forward-Looking Statements
This communication contains
forward-looking statements which include, but are not limited to,
CalciMedica's ongoing and planned clinical trials and the timing,
design, expected patient enrollment thereof and the expected timing
for the release of data from those trials, including its Phase
2b CARPO trial of Auxora for AP with
accompanying SIRS, its ongoing Phase 1/2 CRSPA trial of Auxora in
pediatric patients with AIPT, and its planned Phase 2 KOURAGE trial
of Auxora in AKI with associated AHRF; the potential benefits of
Auxora for the treatment of AP, AKI and AIPT; and the potential of
CalciMedica's proprietary technology to provide therapeutic
benefits in life-threatening inflammatory and immunologic diseases.
These forward-looking statements are subject to the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995. CalciMedica's expectations and beliefs regarding these
matters may not materialize. Actual outcomes and results may differ
materially from those contemplated by these forward-looking
statements as a result of uncertainties, risks, and changes in
circumstances.] Risks and uncertainties that could cause actual
outcomes and results to differ materially from those contemplated
by the forward-looking statements are included under the caption
"Risk Factors" in CalciMedica's Annual Report on Form 10-K for the
year ended December 31, 2023, and
elsewhere in CalciMedica's subsequent reports on Form 10-K, Form
10-Q or Form 8-K filed with the SEC from time to time and available
at www.sec.gov. These documents can be accessed on CalciMedica's
web page at ir.calcimedica.com/financials-filings/sec-filings. The
forward-looking statements contained herein are made as of the date
hereof, and CalciMedica undertakes no obligation to update them
after this date, except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-upcoming-presentation-at-digestive-disease-week-2024-302137229.html
SOURCE CalciMedica, Inc.